13th Congress of the Catalan Transplantation SocietyKidney transplantationMammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation
Section snippets
Methods
This is an observational and prospective study carried out from 2001 to 2014 in a single renal transplant center.
Patients were evaluated immunologically for inclusion in the m-TOR monotherapy protocol.
The immunological evaluation consisted of:
- •
Measuring donor-specific antibodies (DSA) with the use of microsphere cytometry (Luminex).
- •
Evaluation of lymphocyte activity: production of ATP in cultures of T-lymphocytes and CD4+ activated by PHA mitogen (ImmuKnow CyleX).
Patients were enrolled in the
Results
The study population consisted of 98 recipients, 56 men and 42 women with a mean age of 56.0 years (95% CI: 53.8–58.2). Age and sex of recipients and their donors are shown in Table 1. Sirolimus was the m-TOR in 74 cases and everolimus in 24 patients.
Only 7 patients had received induction immunosuppression therapy without CNI, consisting of anti-CD25/thymoglobulin, m-TOR, mycophenolate mofetil (MMF), and prednisone, whereas the remaining 91 were switched to m-TOR at 12 months (p25–p75: 4–36
Discussion
A high degree of discontinuation of m-TOR is observed because of its side effects [14]. Patients in our study had a 100% rate of adherence to treatment, since all patients in the protocol had already received m-TOR with good tolerance.
At the end of follow-up, 15 recipients had dropped out of the study (15.3%), 8 of them without losing their grafts, and all of them have been on the protocol for a long period, at least 16 months (Table 2).
Proteinuria was the side effect responsible for the
References (21)
- et al.
Immunosuppression: evolution in practice and trends, 1994-2004
Am J Transplant
(2006) - et al.
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era
Am J Transplant
(2004) Cardiovascular complications after renal transplantation and their prevention
Transplantation
(2006)- et al.
The natural history of chronic allograft nephropathy
N Engl J Med
(2003) - et al.
Cancer incidence before and after kidney transplantation
JAMA
(2006) - et al.
The role of the mammalian target of rapamycin (m-Tor) in renal disease
J Am Soc Nephrol
(2009) - et al.
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data
BMJ
(2014) KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Am J Transplant
(2009)- et al.
Retrospective analysis of surgical complications following cadaveric kidney transplantation in the modern transplant era
Nephrol Dial Transplant
(2006) - et al.
A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients
Am J Transplant
(2014)
Cited by (4)
Rapamycin for longevity: Opinion article
2019, AgingInhibitory effect of rapamycin on proliferation, migration and fibrosis of human pterygium fibroblasts in vitro
2018, Chinese Journal of Experimental OphthalmologyThe role of sirolimus in proteinuria in diabetic nephropathy rats
2017, Iranian Journal of Basic Medical Sciences
This work was supported by Pfizer Spain.